Bravura Solutions Limited logo

Bravura Solutions Limited (BVS)

Market Closed
CXA CXA
- Market Cap
- P/E Ratio
0% Div Yield
193,945 Volume
- Eps
Want to track BVS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 87 days

Summary

BVS closed yesterday lower, a decrease of 4.2% from Thursday's close, completing a monthly decrease of -1.38%. Over the past 12 months, BVS stock gained 18.96%.
BVS is not paying dividends to its shareholders.
The last earnings report, released on Nov 11, 2025, missed the consensus estimates by -0.11%. On average, the company has fell short of earnings expectations by -0.02%, based on the last three reports. The next scheduled earnings report is due on Mar 10, 2026.
The stock of the company had never split.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Bioventus Inc. (BVS) Q3 2025 Earnings Call Transcript

Bioventus Inc. (BVS) Q3 2025 Earnings Call Transcript

Bioventus Inc. ( BVS ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants David Crawford - Vice President of Investor Relations & Treasurer Robert Claypoole - President, CEO & Director Mark Singleton - Senior VP & CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Ross Osborn - Cantor Fitzgerald & Co., Research Division Caitlin Cronin - Canaccord Genuity Corp., Research Division Presentation Operator Good day, and welcome to the Bioventus Inc. Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.

Seekingalpha | 1 month ago
Bioventus Inc. (BVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Bioventus Inc. (BVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Bioventus Inc. (NASDAQ:BVS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Mark Singleton - Senior VP & CFO Presentation Unknown Analyst Thanks, everyone, for joining us. Before we begin, just the disclaimer.

Seekingalpha | 3 months ago
Bioventus Inc. (BVS) Q2 2025 Earnings Call Transcript

Bioventus Inc. (BVS) Q2 2025 Earnings Call Transcript

Bioventus Inc. (NASDAQ:BVS ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants David Crawford - Vice President of Investor Relations & Treasurer Mark L. Singleton - Senior VP & CFO Robert E.

Seekingalpha | 4 months ago

Bravura Solutions Limited (BVS) FAQ

On which exchange is it traded?

Bravura Solutions Limited is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is BVS.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Mar 10, 2026.

Has Bravura Solutions Limited ever had a stock split?

No, there has never been a stock split.

Bravura Solutions Limited Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Robert E. Claypoole CEO
CXA Exchange
US09075A1088 ISIN
US Country
930 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Bioventus Inc. is a pioneering medical device company that places a strong emphasis on innovating and providing treatments aimed at enhancing the body's intrinsic healing mechanisms. Operating both in the United States and internationally, the company has carved a niche for itself in the medical device industry by offering a wide range of products designed for pain management, surgical solutions, and restorative therapies. With its foundation in 2011 and headquarters in Durham, North Carolina, Bioventus stands as a beacon of advancement in leveraging medical technology to improve patient outcomes.

Products and Services

Pain Treatments: Bioventus' portfolio addresses non-surgical pain through injection therapies and peripheral nerve stimulation products. Key offerings include:

  • Durolane: A treatment for knee osteoarthritis providing pain relief.
  • GELSYN-3: A series of injections for knee osteoarthritis pain management.
  • SUPARTZ: An injectable solution for knee osteoarthritis.
  • Stimrouter: A device aimed at treating chronic peripheral pain.

Surgical Solutions: The company provides surgeons with innovative tools and biomaterials for bone and soft tissue procedures, featuring:

  • Bone Graft Substitutes: Products like Osteoamp, Exponent matrix, Purebone, Signafuse bone graft, Interfuse bone graft, Osteomatrix+ synthetic bone graft, designed to stimulate bone healing.
  • Ultrasonic Products: High-precision devices such as nexus ultrasonic surgical system, bonescalpel surgical solution, SonaStar, and SonicOne ultrasonic cleansing and debridement system for surgeries, including minimally invasive procedures.
  • Extractor: A tool for autologous cell and bone marrow extraction to aid in bone healing.
  • Reficio Bone Matrix: A novel bone graft substitute.

Restorative Therapies: Bioventus also addresses neurologic and musculoskeletal recovery, offering devices that aid in rehabilitation from strokes, multiple sclerosis, or central nervous system disorders. Products include:

  • Exogen: A bone healing system.
  • L300 GO: A system designed to improve foot drop conditions caused by central nervous system disorders.
  • H200 Rehabilitation System: A solution to aid in regaining hand function.
  • Vector: A body weight support system for gait and balance training.
  • Bioness Integrated Therapy System: Offers comprehensive solutions for neurorehabilitation.

The company is also developing the Talisman Pulse Generator and Receiver, a potential breakthrough for peripheral nerve stimulation, showcasing Bioventus' commitment to ongoing innovation and improvement in the field of medical devices.

Contact Information

Address: 4721 Emperor Boulevard
Phone: 919 474 6700